GSA Capital Partners LLP Trims Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

GSA Capital Partners LLP lowered its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 73.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 49,494 shares of the biopharmaceutical company’s stock after selling 140,257 shares during the quarter. GSA Capital Partners LLP’s holdings in Puma Biotechnology were worth $126,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Los Angeles Capital Management LLC acquired a new stake in shares of Puma Biotechnology during the third quarter worth $627,000. Affinity Asset Advisors LLC purchased a new position in Puma Biotechnology during the second quarter worth about $815,000. SG Americas Securities LLC acquired a new stake in Puma Biotechnology in the 1st quarter worth about $57,000. Frazier Life Sciences Management L.P. boosted its stake in Puma Biotechnology by 8.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after buying an additional 246,264 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC increased its stake in shares of Puma Biotechnology by 127.7% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 77,081 shares of the biopharmaceutical company’s stock valued at $409,000 after acquiring an additional 43,229 shares during the last quarter. 61.29% of the stock is owned by hedge funds and other institutional investors.

Puma Biotechnology Price Performance

PBYI stock opened at $3.02 on Tuesday. The stock has a 50-day moving average price of $2.77 and a two-hundred day moving average price of $3.16. The company has a market cap of $148.25 million, a PE ratio of 6.29 and a beta of 1.09. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a 12-month low of $2.22 and a 12-month high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The firm had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. During the same quarter in the prior year, the company earned $0.12 EPS. As a group, research analysts predict that Puma Biotechnology, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PBYI shares. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a research report on Wednesday, November 20th. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.